Clinical Laboratory Core will provide centralized, quality controlled services for specimen processing and management, clinical and virologic laboratory testing, and study-specific tests. The specific functions of the Core are: I. To process biological samples collected in the clinical studies (Project 1, 2) and from dengue vaccine study subjects (Project 3). Core Laboratory will maintain and manage the sample inventory and sample distribution among collaborating laboratories. II. To perform diagnostic serologic and virologic assays for Projects 1, 2 and 3 a. serological diagnosis of acute dengue virus infections using enzyme immunoassay (EIA) and hemagglutination inhibition assay (HAI). b. measurement of dengue serotype-specific neutralizing antibodies by plaque reduction neutralization assay. c. rapid diagnosis of acute dengue virus infections by qualitative dengue virus RT PCR assay. d. isolation of dengue viruses from plasma samples using Toxorrhynchites splendens mosquitoes. III. To quantify the viral burden. a. measurement of dengue virus RNA levels using a fluorogenic RT PCR assay in plasma/serum samples from acutely infected subjects for Projects 1, 2, and 3. b. measurement of NS1 antigen levels by serotype-specific ELISA in plasma/serum of acutely ill subjects for Project 1, 2, and 3. IV. To perform flow cytometry analyses on fresh blood samples for Projects 1 e.g. detection of activated T cells and functional characterization of dengue-specific T and B cells during an acute infection.
The proposed program project represents integrated research activities addressing several important aspects of dengue. The study will be conducted at multiple study sites and laboratories. To support such integrated and complex research activities a Clinical Laboratory Core which will provide centralized, quality controlled services for specimen processing and management and routine clinical and virologic laboratory testing is needed.
|Buddhari, Darunee; Aldstadt, Jared; Endy, Timothy P et al. (2014) Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis 8:e3230|
|Srikiatkhachorn, Anon; Kelley, James F (2014) Endothelial cells in dengue hemorrhagic fever. Antiviral Res 109:160-70|
|Mathew, Anuja; Townsley, Elizabeth; Ennis, Francis A (2014) Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol 9:411-25|
|Rothman, Alan L; Medin, Carey L; Friberg, Heather et al. (2014) Immunopathogenesis Versus Protection in Dengue Virus Infections. Curr Trop Med Rep 1:13-20|
|Srikiatkhachorn, Anon; Spiropoulou, Christina F (2014) Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses. Cell Tissue Res 355:621-33|
|Soller, Babs; Srikiatkachorn, Anon; Zou, Fengmei et al. (2014) Preliminary evaluation of near infrared spectroscopy as a method to detect plasma leakage in children with dengue hemorrhagic fever. BMC Infect Dis 14:396|
|Co, Mary Dawn T; Terajima, Masanori; Thomas, Stephen J et al. (2014) Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children. Viral Immunol 27:375-82|
|Townsley, Elizabeth; Woda, Marcia; Thomas, Stephen J et al. (2014) Distinct activation phenotype of a highly conserved novel HLA-B57-restricted epitope during dengue virus infection. Immunology 141:27-38|
|Rothman, Alan L (2014) DHIM supporting immunologic investigations and the identification of immune correlates of protection. J Infect Dis 209 Suppl 2:S61-5|
|Anderson, Kathryn B; Gibbons, Robert V; Cummings, Derek A T et al. (2014) A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 209:360-8|
Showing the most recent 10 out of 90 publications